{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:37:51Z","timestamp":1792643871154,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.survophthal.2026.10.005","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:40:17Z","timestamp":1791960017000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological strategies for the prevention and treatment of proliferative vitreoretinopathy: A comprehensive review"],"prefix":"10.1016","author":[{"given":"Federico","family":"Giannuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Pio","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4372-8567","authenticated-orcid":false,"given":"Mattia","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Liuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Cestrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"De Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.survophthal.2026.10.005_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000525530","article-title":"Molecular biologic Milieu in rhegmatogenous retinal detachment and proliferative vitreoretinopathy: a literature review","volume":"65","author":"Ananikas","year":"2022","journal-title":"Ophthalmic Res"},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/IIO.0000000000000258","article-title":"Proliferative vitreoretinopathy: a review","volume":"59","author":"Idrees","year":"2019","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0161-6420(83)34588-7","article-title":"The classification of retinal detachment with proliferative vitreoretinopathy","volume":"90","author":"Hilton","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.10.005_bib4","unstructured":"Pastor J.C. Proliferative Vitreoretinopathy: An Overview."},{"issue":"7","key":"10.1016\/j.survophthal.2026.10.005_bib5","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/IAE.0000000000001398","article-title":"Robotic vitreoretinal surgery","volume":"37","author":"Channa","year":"2017","journal-title":"Retina Phila. Pa."},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","article-title":"Proliferative vitreoretinopathy: risk factors and pathobiology","volume":"21","author":"Pastor","year":"2002","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.survophthal.2026.10.005_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00006982-199414050-00005","article-title":"Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery","volume":"14","author":"Girard","year":"1994","journal-title":"Retina Phila. Pa."},{"issue":"7","key":"10.1016\/j.survophthal.2026.10.005_bib8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0161-6420(01)00553-X","article-title":"How to predict proliferative vitreoretinopathy: a prospective study","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF02181181","article-title":"The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor","volume":"226","author":"Bonnet","year":"1988","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/02713680490904142","article-title":"Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy","volume":"30","author":"Rodriguez de la R\u00faa","year":"2005","journal-title":"Curr Eye Res"},{"issue":"9","key":"10.1016\/j.survophthal.2026.10.005_bib11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bjo.2010.190314","article-title":"Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure","volume":"95","author":"Wickham","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006982-198909020-00004","article-title":"Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy","volume":"9","author":"Yoshino","year":"1989","journal-title":"Retina Phila. Pa."},{"issue":"11","key":"10.1016\/j.survophthal.2026.10.005_bib13","first-page":"741","article-title":"Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery","volume":"75","author":"Lle\u00f3 P\u00e9rez","year":"2000","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.10.005_bib14","first-page":"1147","article-title":"Clinical risk factors for proliferative vitreoretinopathy","volume":"107","author":"Cowley","year":"1989","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"11","key":"10.1016\/j.survophthal.2026.10.005_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF00292353","article-title":"Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?","volume":"234","author":"Duquesne","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00176431","article-title":"A multivariate analysis of anatomic success of retinal detachments treated with scleral buckling","volume":"232","author":"Grizzard","year":"1994","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2026.10.005_bib17","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/IAE.0000000000001361","article-title":"Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment","volume":"37","author":"Eliott","year":"2017","journal-title":"Retina Phila. Pa."},{"key":"10.1016\/j.survophthal.2026.10.005_bib18","unstructured":"Vinores, S.A., Campochiaro, P.A., Conway, B.P.: Ultrastructural and Electron-lmmunocytochemical Characterization of Cells in Epiretinal Membranes."},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/0002-9394(75)90222-6","article-title":"Autotransplantation of retinal pigment epithelium in intravitreal diffusion chamber","volume":"80","author":"Mueller-Jensen","year":"1975","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.10.005_bib20","unstructured":"Vinores, S.A., Campochiaro, P.A., McGehee, R. et al.: Ultrastrucfural and Immunocytochemical Changes in Retinal Pigment Epithelium, Retinal Glia, and Fibroblasts in Vitreous Culture."},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/archopht.1986.01050150124042","article-title":"A retinal pigment epithelial cell-derived growth factor(s)","volume":"104","author":"Bryan","year":"1986","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9394(75)90390-6","article-title":"Glial cell proliferation in retinal detachment (massive periretinal proliferation)","volume":"80","author":"Laqua","year":"1975","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.10.005_bib23","unstructured":"Cook, B., Lewis, G.P., Fisher, S.K. et al.: Apoptotic Photoreceptor Degeneration in Experimental Retinal Detachment."},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/08820538.2021.1890791","article-title":"Molecular targets for proliferative vitreoretinopathy","volume":"36","author":"Wu","year":"2021","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/archopht.1997.01100150239014","article-title":"Pathogenic mechanisms in proliferative vitreoretinopathy","volume":"115","author":"Campochiaro","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jcp.1041640219","article-title":"Vasculotropin\/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro","volume":"164","author":"Guerrin","year":"1995","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/1350-9462(96)00012-2","article-title":"Growth factors in the retina and retinal pigmented epithelium","volume":"15","author":"Campochiaro","year":"1996","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2026.10.005_bib28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10792-020-01325-4","article-title":"Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review","volume":"40","author":"Dai","year":"2020","journal-title":"Int Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.10.005_bib29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archopht.1986.01050230123046","article-title":"Intravitreal chemotactic and mitogenic activity: implication of blood-retinal barrier breakdown","volume":"104","author":"Campochiaro","year":"1986","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.10.005_bib30","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archopht.1985.01050050096025","article-title":"Retinal pigment epithelial cells release a chemoattractant for astrocytes","volume":"103","author":"Rowen","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.10.005_bib31","unstructured":"Leschey, K.H., Hackett, S.F., Singer, J.H. et al.: Growth Factor Responsiveness of Human Retinal Pigment Epithelial Cells."},{"issue":"6","key":"10.1016\/j.survophthal.2026.10.005_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0014-4835(05)80003-X","article-title":"Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells","volume":"60","author":"Vinores","year":"1995","journal-title":"Exp Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/archopht.1985.01050040118034","article-title":"Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells","volume":"103","author":"Campochiaro","year":"1985","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","article-title":"An updated classification of retinal detachment with proliferative vitreoretinopathy","volume":"112","author":"Machemer","year":"1991","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/0301-4738.44514","article-title":"Surgical outcomes of transconjunctival sutureless 23-gauge vitrectomy with silicone oil injection","volume":"57","author":"Erakgun","year":"2009","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.10.005_bib36","first-page":"2043","article-title":"Anatomic and functional outcomes of 25-gauge vitrectomy for repair of eyes with rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy","volume":"7","author":"Iwahashi-Shima","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ophtha.2017.09.013","article-title":"Long-term visual outcomes and safety profile of 27-gauge pars plana vitrectomy for posterior segment disease","volume":"125","author":"Khan","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib38","first-page":"100","article-title":"Retrospective comparison of 25-gauge vitrectomy with 20-gauge vitrectomy in the repair of retinal detachment complicated with proliferative vitreoretinopathy","volume":"116","author":"Sato","year":"2012","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"10","key":"10.1016\/j.survophthal.2026.10.005_bib39","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/IAE.0000000000000216","article-title":"Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy","volume":"34","author":"Storey","year":"2014","journal-title":"Retina Phila. Pa."},{"issue":"6","key":"10.1016\/j.survophthal.2026.10.005_bib40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0161-6420(89)32821-1","article-title":"Classification of proliferative vitreoretinopathy used in the silicone study","volume":"96","author":"Lean","year":"1989","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib41","first-page":"335","article-title":"Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11","volume":"115","author":"Abrams","year":"1997","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"11","key":"10.1016\/j.survophthal.2026.10.005_bib42","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2026.10.005_bib43","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2026.10.005_bib44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","article-title":"Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial","volume":"250","author":"Koerner","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.10.005_bib45","first-page":"576","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy","volume":"28","author":"Ghasemi Falavarjani","year":"2014","journal-title":"Eye Lond. Engl."},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/2008-322X.188390","article-title":"Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study","volume":"11","author":"Tousi","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/IAE.0000000000001584","article-title":"Efficacy of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy retinal detachment: a meta-analysis of prospective studies","volume":"38","author":"Zhao","year":"2018","journal-title":"Retina Phila. Pa."},{"issue":"8","key":"10.1016\/j.survophthal.2026.10.005_bib48","first-page":"1223","article-title":"Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation","volume":"104","author":"Lemor","year":"1986","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib49","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/aos.12429","article-title":"Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial","volume":"93","author":"Ahmadieh","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1022509614815","article-title":"Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro","volume":"24","author":"Cai","year":"2001","journal-title":"Int Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2026.10.005_bib51","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.survophthal.2026.10.005_bib52","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","article-title":"Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial","volume":"129","author":"Schaub","year":"2022","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00006982-198300340-00007","article-title":"Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy","volume":"3","author":"Kirmani","year":"1983","journal-title":"Retina Phila. Pa"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib54","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.10.005_bib55","first-page":"1161","article-title":"Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy","volume":"125","author":"Schiff","year":"2007","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"8","key":"10.1016\/j.survophthal.2026.10.005_bib56","first-page":"1261","article-title":"Intraocular application of mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries","volume":"33","author":"Assi","year":"2019","journal-title":"Eye Lond. Engl."},{"issue":"6","key":"10.1016\/j.survophthal.2026.10.005_bib57","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1177\/1120672120976038","article-title":"Intraocular mitomycin C use in the treatment and prophylaxis of proliferative vitreoretinopathy in severe traumatic retinal detachments","volume":"31","author":"G\u00fcrelik","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.18502\/jovr.v16i4.9756","article-title":"Intravitreal methotrexate","volume":"16","author":"Abdi","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2024.10.006","article-title":"A modified intravitreal methotrexate protocol for the prevention of proliferative vitreoretinopathy after silicone oil removal","volume":"9","author":"Liu","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"1\u20132","key":"10.1016\/j.survophthal.2026.10.005_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11010-015-2526-8","article-title":"Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast","volume":"409","author":"Nabai","year":"2015","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.survophthal.2026.10.005_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1569703","article-title":"Effect of methotrexate\/dexamethasone combination on epithelial-mesenchymal transition and inflammation gene expression of human RPE cells in-vitro","volume":"16","author":"Sanie-Jahromi","year":"2025","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.10.005_bib62","article-title":"Use of intravitreal methotrexate infusion in complicated retinal detachment for prevention of proliferative vitreoretinopathy in a pilot study","volume":"13","author":"Jahangir","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib63","first-page":"113","article-title":"Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study","volume":"242","author":"Nourinia","year":"2019","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd"},{"issue":"10","key":"10.1016\/j.survophthal.2026.10.005_bib64","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","article-title":"Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy","volume":"259","author":"Roca","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3928\/23258160-20230220-01","article-title":"Low-dose intravitreal methotrexate for proliferative vitreoretinopathy","volume":"54","author":"Ullah","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"10.1016\/j.survophthal.2026.10.005_bib66","doi-asserted-by":"crossref","DOI":"10.1177\/24741264251323305","article-title":"Postoperative methotrexate to reduce reoperation rate and improve vision in patients with complex retinal detachments, advanced diabetic retinopathy, and trauma","author":"Gibson","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.survophthal.2026.10.005_bib67","unstructured":"Clinicaltrials.gov. Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial (FIXER). https:\/\/clinicaltrials.gov\/study\/NCT06541574."},{"issue":"12","key":"10.1016\/j.survophthal.2026.10.005_bib68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3928\/23258160-20250818-03","article-title":"Intravitreal methotrexate for the treatment and prevention of proliferative vitreoretinopathy in pediatric patients","volume":"56","author":"Bouaziz","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79708-1","article-title":"Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial","volume":"14","author":"Nourinia","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.survophthal.2026.10.005_bib70","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.oret.2024.10.023","article-title":"Association between systemic methotrexate therapy and proliferative vitreoretinopathy","volume":"9","author":"Chen","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib71","first-page":"460","article-title":"Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review","volume":"39","author":"Toh","year":"2025","journal-title":"Eye Lond. Engl."},{"key":"10.1016\/j.survophthal.2026.10.005_bib72","unstructured":"Ci, U.S. Methotrexate for Proliferative Vitreoretinopathy, Eliott et al."},{"issue":"7","key":"10.1016\/j.survophthal.2026.10.005_bib73","article-title":"Post-operative intravitreal methotrexate injections after recurrent retinal detachment repair can reduce the risk and progression of proliferative vitreoretinopathy","volume":"61","author":"Wa","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2026.10.005_bib74","unstructured":"Walter, S.D., Saba, N.J.: Management of Proliferative Vitreoretinopathy with Intravitreal Methotrexate using a Treat-and-Extend Protocol, https:\/\/www.retinasociety.org\/content\/meetingarchive\/2020\/walter-scott-management-of-proliferative-vitreoretinopathy.pdf."},{"issue":"4","key":"10.1016\/j.survophthal.2026.10.005_bib75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/ICO.0000000000002774","article-title":"Corneal toxicity of intravitreal methotrexate used for the treatment of proliferative vitreoretinopathy in silicone oil-filled eyes: a case series","volume":"41","author":"Shen-Sampas","year":"2022","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000293","article-title":"Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy","volume":"4","author":"Benner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib77","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/09273948.2019.1597894","article-title":"Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy","volume":"28","author":"Falavarjani","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2026.10.005_bib78","article-title":"Acupuncture resulting in eye penetration and proliferative vitreoretinopathy \u2013 surgical and medical management with intraocular methotrexate","volume":"18","author":"Denstedt","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2026.10.005_bib79","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/OPTH.S111893","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"10","author":"Sadaka","year":"2016","journal-title":"Clin. Ophthalmol. Auckl. NZ."},{"key":"10.1016\/j.survophthal.2026.10.005_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3648134","article-title":"Anatomical and functional outcomes of vitrectomy with\/without intravitreal methotrexate infusion for management of proliferative vitreoretinopathy secondary to rhegmatogenous retinal detachment","volume":"2021","author":"El Baha","year":"2021","journal-title":"J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2026.10.005_bib81","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/02713683.2010.506970","article-title":"Inhibitory effect of epigallocatechin gallate (EGCG), resveratrol, and curcumin on proliferation of human retinal pigment epithelial cells in vitro","volume":"35","author":"Alex","year":"2010","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib82","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1167\/iovs.12-10418","article-title":"Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine","volume":"54","author":"Umazume","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib83","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2026.10.005_bib84","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.10.005_bib85","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bjophthalmol-2018-312839","article-title":"Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial","volume":"103","author":"London","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2026.10.005_bib86","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00417-018-4105-7","article-title":"Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study","volume":"256","author":"Abdullatif","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0021-5155(02)00698-6","article-title":"Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy","volume":"47","author":"Zheng","year":"2003","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.10.005_bib88","article-title":"Inhibition of proliferation and epithelial mesenchymal transition in retinal pigment epithelial cells by heavy chain-hyaluronan\/pentraxin 3","volume":"7","author":"He","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2026.10.005_bib89","unstructured":"Kim, L.A., Arboleda-Velasquez, J.F., Amarnani, D.: Rho kinase inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition, https:\/\/patents.google.com\/patent\/US20230310446A1\/en, (2023)."},{"issue":"9","key":"10.1016\/j.survophthal.2026.10.005_bib90","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jamaophthalmol.2025.2497","article-title":"Mammalian target rapamycin inhibition as a therapeutic target for prevention of proliferative vitreoretinopathy","volume":"143","author":"Alsoudi","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"23","key":"10.1016\/j.survophthal.2026.10.005_bib91","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/atm.2019.11.90","article-title":"miR-194 suppresses epithelial-mesenchymal transition of retinal pigment epithelial cells by directly targeting ZEB1","volume":"7","author":"Cui","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.survophthal.2026.10.005_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.61.2.1","article-title":"Protein kinase A inhibitor H89 attenuates experimental proliferative vitreoretinopathy","volume":"61","author":"Lyu","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2026.10.005_bib93","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/jbm.a.34198","article-title":"Sustained delivery of paclitaxel using thermogelling poly(PEG\/PPG\/PCL urethane)s for enhanced toxicity against cancer cells","volume":"100","author":"Loh","year":"2012","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib94","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","article-title":"Polymeric micelle stability","volume":"7","author":"Owen","year":"2012","journal-title":"Nano Today"},{"issue":"25","key":"10.1016\/j.survophthal.2026.10.005_bib95","article-title":"Antiangiogenic nanomicelles for the topical delivery of aflibercept to treat retinal neovascular disease","volume":"34","author":"Zhao","year":"2022","journal-title":"Adv Mater Deerfield Beach Fla"},{"issue":"1","key":"10.1016\/j.survophthal.2026.10.005_bib96","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1038\/s41467-022-30474-6","article-title":"A bio-functional polymer that prevents retinal scarring through modulation of NRF2 signalling pathway","volume":"13","author":"Parikh","year":"2022","journal-title":"Nat Commun"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726001475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726001475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:46:14Z","timestamp":1792640774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726001475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":96,"alternative-id":["S0039625726001475"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.10.005","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological strategies for the prevention and treatment of proliferative vitreoretinopathy: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}